Biotech company PsiVac is developing Ixovex-1, the first patented virus with a single base pair mutation able to replicate rapidly, opening potential new treatment options for solid tumors and beyond.

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...